Published online Oct 26, 2021. doi: 10.12998/wjcc.v9.i30.9151
Peer-review started: April 19, 2021
First decision: June 24, 2021
Revised: July 3, 2021
Accepted: August 24, 2021
Article in press: August 24, 2021
Published online: October 26, 2021
Processing time: 184 Days and 17.8 Hours
Hepatocellular carcinoma is an aggressive tumor, and its latency and lack of clinical symptoms mean that most patients are already in the late stage when diagnosed. Large tumor volume and metastasis are the main reasons for not attempting surgery. Portal vein embolization and associated liver partition and portal vein ligation for staged hepatectomy are commonly used in clinical practice to increase the volume of remnant liver to allow surgical resection; however, research in this area is currently lacking.
A 48-year-old male patient with a history of viral hepatitis B for at least 30 years attended our center with a hepatic space-occupying lesion detected 3 d previously. Enhanced computed tomography scanning of the upper abdomen revealed a large mass in the right lobe of the liver, centered on the right posterior lobe, with the larger section measuring about 14 cm × 10 cm × 14 cm. He successfully underwent conversion therapy for a large right liver tumor after combined hepatic artery ligation and transcatheter arterial chemoembolization, and finally had an opportunity to undergo right hemi-hepatectomy and cholecystectomy. He remained asymptomatic with no obvious abnormalities on computed tomography scanning review at 2 mo after surgery.
This case highlights new ideas and provides a reference for conversion therapy of large liver tumors.
Core Tip: Portal vein embolization associated liver partition and portal vein ligation for staged hepatectomy, and transcatheter arterial chemoembolization (TACE) are commonly used in conversion therapy of advanced liver cancer. However, the therapeutic effects of portal vein embolization and TACE are limited, and associating liver partition and portal vein ligation for staged hepatectomy is associated with high morbidity and mortality. We therefore combined hepatic artery ligation with TACE, which has a longer treatment cycle and slower compensation of the contralateral liver compared with the above treatments but which may make R0 resection feasible with less surgical complications and with good postoperative recovery.